Nicoleta Bîscă *
* Nicoleta Bîscă – cercetător științific gr. I, Institutul Clmic de Pneumoftiziologie “Marius Nasta” – București
Abstract
A new class of agent, compounds that block leukotrienes (leukotriene receptor antagonists and 5-lipoxygenase). have demonstrated improvement in asthma control. Singulair (Montelukast sodium, MSD) is a potent and selective once-daily oral leukotriene receptor antagonist, that is indicated for treatment of chronic asthma. Singulair improves respiratory function and asthmatic related symptoms in adults and children with chronic asthma. Singulair has been shown to provide an additional efficacy in patient not adequately controlled with inhaled corticosteroidsand to allow tapering of inhaled steroid doses. In addition Singulair has been shown to prevent exercise – induced bronchoocnstriction in adults in children. Singulair is available in a 10 mg tablet for adult patient 15 years of age and older and in a 5 mg cherry-flavored, chewable tablet for children 6 to 14 years of age. No serious drug-relatec. adverse experience were reported by any patient receiving Singulair.